Emerging Strategies for ALK+ NSCLC

Panelists explore emerging therapeutic strategies focused on enhancing selectivity and minimizing off-target effects. Research includes novel inhibitors, degraders, and combination regimens that may improve outcomes in resistant disease.

They stress that early-phase clinical trials have shown promising signals of activity even in heavily pretreated patients. The development of these strategies underscores the ongoing innovation within precision oncology for lung cancer.

Panelists conclude that as new agents progress through clinical evaluation, the field is moving closer to long-term disease suppression and improved survival in patients with treatment-resistant ALK-positive disease.